Compare Novo Nordisk A/S (NVO) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tripadvisor Inc Common Stock — how do they compare? Novo Nordisk A/S trades at $38.63 (market cap $165.31B), while Tripadvisor Inc Common Stock trades at $8.71 (market cap $1.01B). The key difference: Novo Nordisk A/S is far larger — about 163.7× Tripadvisor Inc Common Stock's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| NVO | TRIP | |
|---|---|---|
Market Cap | $165.31B | $1.01B |
Volume | 11,432,838 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $16.72 |
52-Week Low | $35.29 | $8.04 |
Typical Hold Time | 116 Days | 57 Days |
Enterprise Value | $179.56B | $1.06B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
TripAdvisor (TRIP) trades at $8.675, up 0.52% on the day, but remains near its 52-week low of $8.27 (Defense World, 2026-09-25). The stock shows a mixed technical picture with bullish oscillators but bearish moving averages. Fundamentally, revenue grew to $1.89B in 2025 with net income improving to $40M, though recent quarterly earnings have missed expectations. The company faces headwinds from AI competition in travel planning but maintains strong brand recognition through its Travelers' Choice Awards.
The investment outlook is cautious. While analyst consensus suggests 56% upside to the $13.58 price target, recent insider selling and earnings misses highlight execution risks. The key opportunity lies in the potential monetization of Viator and TheFork sale, but competitive pressure from AI platforms remains a significant threat to long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
